Alamar Biosciences Announces First Five Distribution Partners, Expanding Commercial Support in Asia Pacific

March 19, 2025 06:59 AM PDT | By Cision

Google News:

Alamar Biosciences Announces First Five Distribution Partners, Expanding Commercial Support in Asia Pacific — Image source: Kalkine Media

Recent News

SignalRank marks 2-year milestone with strong performance, announces v...

Informative Research Integrates Accountchek® With Halcyon To Automate...

Walmart to pass on tariff burden to shoppers, braces for margin volati...

NEXPACE launches MapleStory N, NXPC token, charting new chapter for Ma...

FREMONT, Calif., March 19, 2025 /PRNewswire/ -- Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, is pleased to announce the signing of five new distribution partners to expand its global presence. The company has partnered with established industry leaders across key international markets to enhance access to its innovative proteomics technologies.

The newly signed distribution partners include:

GeneWorks – Australia and New Zealand
Genomax – Singapore
PhileKorea – South Korea
Scrum Inc. – Japan
Spinco – India

"We are excited to welcome these outstanding partners to the Alamar network," said Yuling Luo, Ph.D., Founder, Chairman and CEO of Alamar Biosciences, "Their deep expertise in the life sciences industry and strong regional presence will allow us to bring our next-generation proteomics solutions to more researchers and clinicians worldwide."

Alamar's technology empowers scientists to achieve groundbreaking insights in biomarker discovery, drug development, and disease research. Through these new partnerships, researchers in Asia-Pacific will now have enhanced access to Alamar's cutting-edge platforms and technical support.

Alamar remains committed to supporting the scientific community with best-in-class tools that enable high-sensitivity protein analysis. For more information on Alamar's distribution network and solutions, visit alamarbio.com.

About Alamar Biosciences, Inc.

Alamar Biosciences is a privately held life sciences company with a mission to power precision proteomics to enable the earliest detection of disease. The company's proprietary NULISA™ Platform along with the ARGO™ HT System work seamlessly with the latest advances in genomics to achieve single digit attomolar detection sensitivity, greatly surpassing the most sensitive protein detection technology on the market today. For more information, please visit alamarbio.com.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations, and video (Content) is a service of Kalkine Media LLC., having Delaware File No. 4697309 (“Kalkine Media, we or us”) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.

This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.